This article is Part VI of a review series covering all the initial public offerings for the biotech and pharmaceutical industries in 2021. Pt. I and Pt. II provided an overview of 2021 IPOs by therapy area, technology, and therapeutic class. Pt. III and Pt. IV provided a deep dive into the 2021 IPOs for oncology-focused companies, while P.t V provided a deep dive into the 2021 IPOs for neurology-focused companies.
This short article takes a deeper look into the 2021 IPOs for small molecule and biotechnology-based therapeutics being developed by immunology-focused companies, including:
- S1P1 modulators for inflammatory diseases
- An IL-17 antagonist from DEL screening
- An immune cell-based therapy
- An anti-TL1A antibody
- And more
request a trial
Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more.
Interested in learning more? Submit this form to request a trial.